04:50 AM EST, 11/07/2024 (MT Newswires) -- Revolution Medicines ( RVMD ) reported a Q3 net loss late Wednesday of $0.94 per diluted share, compared with a loss of $0.99 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.90.

The company did not report any revenue for the quarter ended Sept. 30. Analysts surveyed by Capital IQ expected $350,000.

Revolution reiterated the projected full-year 2024 net loss guidance of between $560 million and $600 million.

The company projected that its current cash, cash equivalents and marketable securities can fund planned operations into 2027.

Price: 58.00, Change: -1.42, Percent Change: -2.39